Skip to main content
SpringerLink
Log in

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Drugs - Real World Outcomes : 11 Apr 2022. Available from: URL: https://doi.org/10.1007/s40801-022-00300-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders. Reactions Weekly 1902, 8 (2022). https://doi.org/10.1007/s40278-022-13152-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-13152-x

Search

Navigation